Last reply 11 months ago
Narrowing drugs choices down

Hi,

It’s a worry that they are narrowing drug choices down for the treatment of ms. If you need them it’s not good that they are abandoning some of the choices.
What if the drug doesn’t agree with you , what happens then ? Choice is always a good thing for this and many reasons. It might not affect people who are on the ones they are abandoning like copoxone but it will affect new people to ms and people who might need them in the future .

How do we make our voice heard. It’s not okay to affect our lives and limiting choice even more because of their cost cutting !

Rachael

Add categories

Browse categories and add by clicking on them

You can remove current categories below by clicking the ‘x’.


nutshell88
11 months ago

You never know Rachellouise they might of found something naughty in them and never wanted to say it out loud or maybe they want more people to use new treatments to fund their companies. Pardon My mser brain theories 😂


stumbler
11 months ago

@rachaellouise , these are the original “CRAB” drugs, which were the only option about 20 years ago. To date, they have been regarded as first-line drugs, even though more effective drugs have been introduced.

There is presently a choice of 14 drugs (including Ocrevus and Mavenclad), with options on drug delivery, e.g. oral, infusion, etc..

Reducing this choice is just an evolutionary step and will prompt Neuros to consider better treatments at the outset.

Join Shift.ms to reply to this post.

Become part of the community so you can chat, compare and learn from other MSers.